<style face="normal" font="default" size="100%">323 Preclinical development of AB-1015, an integrated circuit T cell therapy containing an ALPG/MSLN logic gate and FAS/PTPN2 shRNA-miR, for the treatment of ovarian cancer</style>

Drupal-HighWire